[go: up one dir, main page]

PE20210116A1 - Administracion oral de analogos del peptido glp-1 - Google Patents

Administracion oral de analogos del peptido glp-1

Info

Publication number
PE20210116A1
PE20210116A1 PE2020000457A PE2020000457A PE20210116A1 PE 20210116 A1 PE20210116 A1 PE 20210116A1 PE 2020000457 A PE2020000457 A PE 2020000457A PE 2020000457 A PE2020000457 A PE 2020000457A PE 20210116 A1 PE20210116 A1 PE 20210116A1
Authority
PE
Peru
Prior art keywords
glp
oral administration
peptide analogs
formulations
peptide
Prior art date
Application number
PE2020000457A
Other languages
English (en)
Inventor
Sergei Pechenov
Puneet Tyagi
Janardhanan Anand Subramony
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of PE20210116A1 publication Critical patent/PE20210116A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a formulaciones para administracion oral de analogos del peptido GLP-1 y metodos para administrar estos, en donde dichas formulaciones comprenden una composicion farmaceutica de un analogo bislipidado del peptido GLP-1 y quenodesoxicolato sodico o galato de propilo. Estas formulaciones son utiles para el tratamiento de la diabetes tipo 2.
PE2020000457A 2017-10-31 2018-10-30 Administracion oral de analogos del peptido glp-1 PE20210116A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579186P 2017-10-31 2017-10-31
PCT/IB2018/058514 WO2019087083A2 (en) 2017-10-31 2018-10-30 Oral delivery of glp-1 peptide analogs

Publications (1)

Publication Number Publication Date
PE20210116A1 true PE20210116A1 (es) 2021-01-19

Family

ID=66331379

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000457A PE20210116A1 (es) 2017-10-31 2018-10-30 Administracion oral de analogos del peptido glp-1

Country Status (23)

Country Link
US (1) US11173124B2 (es)
EP (1) EP3703817A4 (es)
JP (1) JP2021501172A (es)
KR (1) KR20200081411A (es)
CN (1) CN111655338A (es)
AR (1) AR116451A1 (es)
AU (1) AU2018360382A1 (es)
BR (1) BR112020008220A2 (es)
CA (1) CA3079376A1 (es)
CL (1) CL2020001131A1 (es)
CO (1) CO2020005485A2 (es)
CR (1) CR20200185A (es)
DO (1) DOP2020000082A (es)
EA (1) EA202091095A1 (es)
IL (1) IL274096A (es)
MA (1) MA50047A (es)
MX (1) MX2020004497A (es)
PE (1) PE20210116A1 (es)
PH (1) PH12020551018A1 (es)
SG (1) SG11202003627PA (es)
TW (1) TW201932139A (es)
WO (1) WO2019087083A2 (es)
ZA (1) ZA202003149B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079376A1 (en) 2017-10-31 2019-05-09 Medimmune Limited Oral delivery of glp-1 peptide analogs
GB2616223A (en) * 2020-11-27 2023-08-30 D&D Pharmatech Inc Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
FR3120189B1 (fr) * 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
CN118715006A (zh) * 2022-02-22 2024-09-27 阿斯利康(瑞典)有限公司 可压缩癸酸钠配制品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
EP2679270B1 (en) * 2011-02-24 2016-11-09 Hisamitsu Pharmaceutical Co., Inc. Glp-1 analogue composition for microneedle devices
WO2013148966A1 (en) * 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
RU2671406C2 (ru) * 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
JP2016524617A (ja) 2013-05-30 2016-08-18 ノヴォ ノルディスク アー／エス 糖尿病の治療のための新規な経口医薬組成物
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
CN106366166A (zh) * 2016-08-30 2017-02-01 苏州普罗达生物科技有限公司 脑源性神经营养因子促进剂多肽及应用
CA3079376A1 (en) * 2017-10-31 2019-05-09 Medimmune Limited Oral delivery of glp-1 peptide analogs

Also Published As

Publication number Publication date
ZA202003149B (en) 2021-06-30
TW201932139A (zh) 2019-08-16
EA202091095A1 (ru) 2020-09-18
AU2018360382A1 (en) 2020-06-18
US11173124B2 (en) 2021-11-16
MA50047A (fr) 2020-07-08
AR116451A1 (es) 2021-05-12
EP3703817A4 (en) 2021-08-18
CN111655338A (zh) 2020-09-11
CO2020005485A2 (es) 2020-05-15
CL2020001131A1 (es) 2020-10-23
MX2020004497A (es) 2020-08-13
CR20200185A (es) 2020-06-19
WO2019087083A3 (en) 2019-08-08
IL274096A (en) 2020-06-30
BR112020008220A2 (pt) 2020-10-27
CA3079376A1 (en) 2019-05-09
JP2021501172A (ja) 2021-01-14
SG11202003627PA (en) 2020-05-28
DOP2020000082A (es) 2020-08-31
PH12020551018A1 (en) 2021-05-31
KR20200081411A (ko) 2020-07-07
US20200323782A1 (en) 2020-10-15
WO2019087083A2 (en) 2019-05-09
EP3703817A2 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
MX369259B (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
ECSP21051833A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
PE20200678A1 (es) Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2)
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
PE20241305A1 (es) Analogos de amilina
MX392606B (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
MX2018006903A (es) Composicion farmaceutica.
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
AR083528A1 (es) Analogos de peptido insulinotropico dependiente de glucosa
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CO2025007025A2 (es) Formulaciones orales compactables de ibutamoren
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
NI201200196A (es) Agentes terapéuticos 976